Keyword: Forbion Capital Partners
The agreement gives Novo the chance to add an anti-apoC3 antibody treatment for abnormal lipid levels to its pipeline.
The Forbion-led series B tees up Inflazome to trial its NLRP3 inflammasome inhibitors in several inflammatory diseases.
The Forbion-led series C round sets Omeicos up to run a phase 2 trial of its small molecule analogue of a natural omega-3 fatty acid metabolite.
The addition of €90 million since the first close in July means Forbion has pulled in almost twice as much money as it managed for its third fund.
Medical device and diagnostics startups were integral to Forbion’s first three funds but will receive only a fraction of the $316 million fourth fund.
The bumper first close of the fund follows a period in which Forbion has shown a knack for picking winners.
The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.
The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.
European VC firm Forbion, New Science Ventures and BioGeneration Ventures have helped bump up a $19 million series B round for Escalier Biosciences.
The haul makes BioDiscovery 5 the largest fund dedicated to biotechs and medical devices in Europe and tees up De Rothschild to invest in 17 firms.